


Please type a plus sign (+) inside this box → ☐



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known

Application Number	10/036,988
Filing Date	December 31, 2001
First Named Inventor	Roger L. Papke
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	UF-293

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, or Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
[Signature]	U1	5,212,188		Caldwell <i>et al.</i>	05-18-1993	TECH CENTER 1600/2900
	U2	5,597,919		Dull <i>et al.</i>	01-28-1997	All
	U3	6,218,383	B1	Bencherif	04-17-2001	All
	U4					
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					
	U15					
	U16					
	U17					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1							
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner
Signature

[Signature]

Date

Considered


3/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/036,988
Filing Date	December 31, 2001
First Named Inventor	Roger L. Papke
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	UF-293

RECEIVED

APR 05 2002

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate) item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
5	R1	ADLER, L.E. <i>et al.</i> "Normalization by Nicotine of Deficient Auditory Sensory Gating in the Relatives of Schizophrenics" <i>Biol. Psychiatry</i> , 1992, 32:607-616.	
5	R2	ADLER, L.E. <i>et al.</i> "Normalization of Auditory Physiology by Cigarette Smoking in Schizophrenic Patients" <i>Am. J. Psychiatry</i> , 1993, 150:1856-1861.	
5	R3	ADLER, L.E. <i>et al.</i> "Schizophrenia, Sensory Gating, and Nicotinic Receptors" <i>Schizophr. Bull.</i> , 1998, 24(2):189-202.	
5	R4	ARNERIC, S.P. <i>et al.</i> "Neuronal Nicotinic Acetylcholine Receptors" <i>Psychopharmacology: The Fourth Generation of Progress</i> , 1995, pp. 95-110.	
5	R5	BENCHERIF, M. <i>et al.</i> "RJR-2403: A Nicotinic Agonist with CNS Selectivity I. <i>In Vitro</i> Characterization" <i>J. Pharmacol. Exp. Ther.</i> , 1996, 279:1413-1421.	
5	R6	BENOWITZ, N.L. "Pharmacology of Nicotine: Addiction and Therapeutics" <i>Annu. Rev. Pharmacol. Toxicol.</i> , 1996, 36:597-613.	
5	R7	COSFORD, N.D.P. <i>et al.</i> "(S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl) pyridine Maleate (SIB-1508Y): A Novel Anti-Parkinsonian Agent with Selectivity for Neuronal Nicotinic Acetylcholine Receptors" <i>J. Med. Chem.</i> , 1996, 39:3235-3237.	
5	R8	COSFORD, N.D.P. <i>et al.</i> "Recombinant human receptors and functional assays in the discovery of altinidine (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist" <i>Pharm. Acta. Helv.</i> , 2000, 74:125-130.	
5	R9	DAMAJ, M.I. <i>et al.</i> "Antinociceptive and Pharmacological Effects of Metanicotine, a Selective Nicotinic Agonist" <i>J. Pharmacol. Exp. Ther.</i> , 1999, 291(1):390-398.	
5	R10	DE FIEBRE, C.M. <i>et al.</i> "Characterization of a Series of Anabaseine-Derived Compounds Reveals that the 3-(4)-Dimethylaminocinnamylidene Derivative is a Selective Agonist at Neuronal Nicotinic $\alpha 7^{125}$ I- α -Bungarotoxin Receptor Subtypes" <i>Mol. Pharmacol.</i> , 1995, 47:164-171.	
5	R11	DONNELLY-ROBERTS, D.L. <i>et al.</i> "ABT-594 [(R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine]: A Novel, Orally Effective Analgesic Acting via Neuronal Nicotinic Acetylcholine Receptors: I. <i>In Vitro</i> Characterization" <i>J. Pharmacol. Exp. Ther.</i> , 1998, 285:777-786.	
5	R12	FLORES, C.M. <i>et al.</i> "A Subtype of Nicotinic Cholinergic Receptor in Rat Brain is Composed of $\alpha 4$ and $\beta 2$ Subunits and is Up-regulated by Chronic Nicotine Treatment" <i>Mol. Pharmacol.</i> , 1992, 41:31-37.	
5	R13	FREEDMAN, R. <i>et al.</i> "Schizophrenia and Nicotinic Receptors" <i>Harvard Rev. Psychiatry</i> , 1994, 2(4):179-192.	

TECH CENTER 1600/2900

Examiner
Signature

Bridan

Date
Considered


3/18/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

5

Application Number

10/036,988

Filing Date

December 31, 2001

First Named Inventor

Roger L. Papke

Group Art Unit

1633

Examiner Name

Attorney Docket Number

UF-293

Complete if Known

RECEIVED

APR 05 2002

NON PATENT LITERATURE DOCUMENTS

TECH CENTER 1600/2900

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
5	R14	FREEDMAN, R. <i>et al.</i> "The $\alpha 7$ -nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia" <i>J. of Chemical Neuroanatomy</i> , 2000, 20:299-306.	
5	R15	GERZANICH, V. <i>et al.</i> " $\alpha 5$ Subunit Alters Desensitization, Pharmacology, Ca^{++} Permeability and Ca^{++} Modulation of Human Neuronal $\alpha 3$ Nicotinic Receptors" <i>J. Pharmacol. Exp. Ther.</i> , 1998, 286(1):311-320.	
6	R16	HALVORSEN, S.W. AND D.K. BERG "Subunit Composition of Nicotinic Acetylcholine Receptors from Chick Ciliary Ganglia" <i>J. Neurosci.</i> , June 1990, 10(6):1711-1718.	
1	R17	HOLLADAY, M.W. <i>et al.</i> "Neuronal Nicotinic Acetylcholine Receptors as Targets for Drug Discovery" <i>J. Med. Chem.</i> , December 19, 1997, 40(26):4169-4194.	
5	R18	LIPPIELLO, P.M. <i>et al.</i> "RJR-2403: A Nicotinic Agonist with CNS Selectivity II. <i>In Vivo</i> Characterization" <i>J. Pharmacol. Exp. Ther.</i> , 1996, 279:1422-1429.	
5	R19	LLOYD, G.K. <i>et al.</i> "The Potential of Subtype-Selective Neuronal Nicotinic Acetylcholine Receptor Agonists as Therapeutic Agents" <i>Life Sciences</i> , 1998, 62(17/18):1601-1606.	
5	R20	LLOYD, G.K. AND M. WILLIAMS "Neuronal Nicotinic Acetylcholine Receptors as Novel Drug Targets" <i>J. Pharmacol.</i> , 2000, 292(2):461-467.	
5	R21	MEYER, E.M. <i>et al.</i> "3-[2,4-Dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat $\alpha 7$ receptors and improves memory-related behaviors in a mecamylamine-sensitive manner" <i>Brain Res.</i> , 1997, 768:49-56.	
5	R22	MIHAILESCU, S. AND R. DRUCKER-COLIN "Nicotine, Brain Nicotinic Receptors, and Neuropsychiatric Disorders" <i>Arch. Med. Res.</i> , 2000, 31:131-144.	
6	R23	MILLER, C. "Genetic Manipulation of Ion Channels: A New Approach to Structure and Mechanism" <i>Neuron</i> , 1988, 2:1195-1205.	
6	R24	MULLE, C. <i>et al.</i> "Existence of Different Subtypes of Nicotinic Acetylcholine Receptors in the Rat Habenulo-interpeduncular System" <i>J. Neurosci.</i> , August 1991, 11(8):2588-2597.	
6	R25	NEWHOUSE, P.A. <i>et al.</i> "Nicotinic System Involvement in Alzheimer's and Parkinson's Diseases" <i>Drugs Aging</i> , September 1997, 11(3):206-228.	
5	R26	NEWHOUSE, P.A. AND M. KELTON "Nicotinic systems in central nervous systems disease: degenerative disorders and beyond" <i>Pharm. Acta. Helv.</i> , 2000, 74:91-101.	

Examiner
Signature

[Signature]

Date
Considered


3/18/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/036,988
Filing Date	December 31, 2001
First Named Inventor	Roger L. Papke
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	UF-293

Sheet

4

of

5

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
5	R27	PAPKE, R.L. "The Kinetic Properties of Neuronal Nicotinic Receptors: Genetic Basis of Functional Diversity" <i>Prog. Neurobiol.</i> , 1993, 41:509-531.	
6	R28	PAPKE, R.L. "Activation and inhibition of rat neuronal nicotinic receptors by ABT-418" <i>Br. J. Pharmacol.</i> , 1997, 120:429-438.	
6	R29	PAPKE, R.L. <i>et al.</i> "The Activation and Inhibition of Human Nicotinic Acetylcholine Receptor by RJR-2403 Indicate a Selectivity for the $\alpha 4 \beta 2$ Receptor Subtype" <i>J. Neurochem.</i> , 2000, 75:204-216.	
5	R30	PAPKE, R.L. <i>et al.</i> " $\alpha 7$ Receptor-selective agonists and modes of $\alpha 7$ receptor activation" <i>Eur. J. Pharmacol.</i> , 2000, 393:179-195.	
6	R31	PAPKE, R.L. <i>et al.</i> "Inhibition of Wild-Type and Mutant Neuronal Nicotinic Acetylcholine Receptors by Local Anesthetics" <i>Mol. Pharm.</i> , 2001, 60:1365-1374.	
5	R32	RUSTED, J.M. AND P.A. NEWHOUSE "Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease" <i>Behav. Brain Res.</i> , 2000 113:121-129.	
5	R33	SANBERG, P.R. <i>et al.</i> "Treatment of Tourette's syndrome with mecamylamine" <i>Lancet</i> , August 29, 1998, 352:705-706.	
6	R34	SILVER, A.A. <i>et al.</i> "Case Study: Long-Term Potentiation of Neuroleptics with Transdermal Nicotine in Tourette's Syndrome" <i>J. Am. Acad. Child Adolesc. Psychiatry</i> , December 1996, 35:1631-1636.	
5	R35	SULLIVAN, J.P. <i>et al.</i> "ABT-089 [2-Methyl-3-(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties" <i>J. Pharmacol. Exp. Ther.</i> , 1997, 283(1):235-246.	
5	R36	VERNIER, J. <i>et al.</i> "4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]-phenol Hydrochloride (SIB-1553A): A Novel Cognitive Enhancer with Selectivity for Neuronal Nicotinic Acetylcholine Receptors" <i>J. Med. Chem.</i> , 1999, 42:1684-1686.	
5	R37	VIDAL, C. "Nicotinic Receptors in the Brain" <i>Mol. Chem. Neuropathol.</i> , 1996, 28:3-11.	
6	R38	WANG, F. <i>et al.</i> "Assembly of Human Neuronal Nicotinic Receptor $\alpha 5$ Subunits with $\alpha 3$, $\beta 2$, and $\beta 4$ Subunits" <i>J. Biol. Chem.</i> , July 1996, 271(30):17656-17665.	
6	R39	WEBSTER, J.C. <i>et al.</i> "Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain" <i>Br. J. of Pharmacol.</i> , 1999, 127:1337-1348.	

Examiner
Signature

Brill

Date
Considered


3/18/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/036,988
Filing Date	December 31, 2001
First Named Inventor	Roger L. Papp
Gr up Art Unit	1633
Examiner Name	APR 05 2002
Attorney Docket Number	UF-293

Sheet 5 of 5

NON PATENT LITERATURE DOCUMENTS

TECH CENTER 1800/2000


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
6	R40	WHITING, P.J. AND J.M. LINDSTROM "Purification and Characterization of a Nicotinic Acetylcholine Receptor from Chick Brain" <i>Biochemistry</i> , 1986, 25:2082-2093.	
5	R41	WILLIAMS, M. <i>et al.</i> "Neuronal Nicotinic Acetylcholine Receptors" <i>Drug News Perspect.</i> , May 1994, 7(4):205-223.	
6	R42	YOUNG, J.M. <i>et al.</i> "Mecomyamine: New Therapeutic Uses and Toxicity/Risk Profile" <i>Clin. Ther.</i> , 2001, 23(4):532-565.	
	R43		
	R44		
	R45		
	R46		
	R47		
	R48		
	R49		
	R50		
	R51		
	R52		

Examiner Signature		Date Considered	3/18/02
-----------------------	--	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



JUL 21 2003

Please type (+) inside this box ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/036,988
Filing Date	December 31, 2001
First Named Inventor	Roger L. Papke
Group Art Unit	1614
Examiner Name	Brian Yong S. Kwon
Attorney Docket Number	UF-293

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	U1	6,277,855	B1	Yerxa	08-21-2001	All
	U2	5,977,144		Meyer et al.	11-02-1999	All
	U3	5,885,998		Bencherif et al.	03-23-1999	All
	U4	5,726,316		Crooks et al.	03-10-1998	All
	U5					
	U6					
	U7					
	U8					
	U9					
	U10					
	U11					
	U12					
	U13					
	U14					
	U15					
	U16					
	U17					

RECEIVED
JUL 23 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	F1							
	F2							
	F3							
	F4							
	F5							
	F6							
	F7							
	F8							
	F9							
	F10							

Examiner Signature

Date Considered

8/1/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.